Pre-Conference Day

As ADCs become more crowded with Topo1 and MMAE payloads across oncology indications, the need for payload and targeting moiety differentiation is crucial to develop the next wave of ADCs providing long-term benefit to oncology patients. Join this seminar day to stay ahead of the ADC design curve across non-cytotoxic payloads, high DAR ADC design, site–specific conjugation technologies, and emerging multi payload ADC design rationale and performance.

Spotlighting the Versatility & Emerging Therapeutic Profile of BPT567 – A Novel PD1-IL18 Based Immunoconjugate

• Detailing Bright Peak protein engineering and protein conjugation to construct BPT567 and other antibody-protein conjugates
• Showcasing preclinical activity of immunoconjugate BPT567 with IL-18 payload
• Reviewing plans for ongoing Phase 1/2a in-human study and highlighting the need for novel ADC payload innovation

Whilst the path to the clinic is relatively established for cytotoxic ADCs, in–depth knowledge of ADC MoA and behavior targeting tumor cells remains elusive, especially for ADCs with novel payloads and targeting moieties. Attend this seminar day to leverage PD and systems pharmacology modeling to investigate ADC tumor targeting behavior, unlock insights into non-cytotoxic ADC MoA, and model applications of bioconjugates beyond oncology. 

Showcasing Novel Pharmacology & Translational Aspects of SOT106 Targeting LRRC15 in Solid Tumors

• Describing pharmacological characterization of SOT106, including LRRC15 expression within different cell populations in the TME with emphasis on pivotal role in tumor biology
• Developing SOT106 diagnostic antibody tailored to optimize patient selection to identify those who could benefit from therapy
• Exploring the potential of SOT106 combination therapies and how these approaches can elevate its full therapeutic potential

Despite blockbuster ADCs moving to earlier-line treatments and challenging oncology standard of care, poor tolerability remains the limiting factor to widen therapeutic index and true success in patients. Don’t miss this seminar day characterizing and mitigating on and off–target ADC toxicities, utilizing in vivo and in vitro models to predict ADC clinical safety profiles, and spotlighting differentiated ADC design with enhanced tolerability profiles front and center.

Leveraging In Vitro Models to Support ADC Preclinical Safety Assessments to Accurately Predict & Quantify Clinical Toxicity Profiles 

• Applying advanced in vitro models to complement ADC safety strategy alongside in vivo preclinical models
• Integrating bioanalytical methods with in vitro toxicity to improve early-stage clinical toxicity predictions
• Assessing key toxicities commonly observed in clinical settings to prioritize and select the safest ADC molecules

In an ever-busy clinical landscape and the rise of ADC patient resistance, the role of combinations has become more important than ever to bring better ADC treatments to oncology patients faster. Join this long-standing seminar day to overview ADC clinical combination leaders, assess applications of dual payload ADCs to tackle patient payload resistance, and delve into rationale-driven practices to smartly select and investigate the right ADC combination partners.

Developing Next-Generation Immunostimulatory Dual Payload ADCs to Enhance Therapeutic Index & Tackle Patient Resistance 

• Exploring targeted delivery of cytotoxins and immune agonists simultaneously
• Explaining how dual mechanisms enable direct tumor cell killing and activation of anti-tumor immunity
• Demonstrating immunostimulatory ADC enhanced efficacy and therapeutic index

Properly understanding ADC PK/PD and in vivo stability is crucial to best inform clinical performance and trial design. Don’t miss this brand-new seminar day exploring bioanalytical strategy across development phases, insights into LC-MS method development, and case studies of in vivo biotransformation impacting PK/PD and stability properties to understand how to efficiently leverage bioanalytical technologies to best characterize your ADC clinical material.

Evaluating Opportunities to Improve ADC Bioanalytical Efficiency & Understand Future Directions for ADC Immunogenicity Characterization

• Explaining challenges in ADC PK characterization across mAb, free payload, and conjugate
• Assessing bioanalytical and regulatory strategy required ADC bioanalysis in late-stage development
• Immunogenicity assessment of ADCs and what have we learned and future directions

As we see the rise of ADCs with new payload and targeting moiety innovation, ensuring your candidates meet CQA standards is paramount to understand and control all the factors influencing ADC efficacy and safety profiles. Join this new seminar day to identify, understand and meet the breadth of ADC CQAs across DAR, charge variance, impurity, novel payload characterization and beyond to maximize ADC quality and process control.

Assessing Impact of ADC Properties on DAR Analyses by Hydrophobic Interaction Chromatography

• Outlining analytical methods for determining DAR, which is one of the CQAs) for ADCs
• Investigating which ADC properties impact hydrophobic interaction chromatography (HIC)
• Highlighting that the linker length of drug linkers significantly impacts on peak separation in HIC

In fast-paced ADC development, optimizing scale up, tech transfer, and setting specifications are all vital to assure confidence in regulatory submissions. Attend this seminar day tailored towards late-stage manufacturing to align ADC reg CMC strategy with global regulatory expectations, understand opportunities to streamline CMC under ADC development timelines, and explore insights to improve ADC DP manufacturing and stability in late–stage and post approval stages.

Delving into ADC Stability Budgets to Understand & Maintain Product Stability Across Clinical & Commercial-Stage ADC Process Development

• Understanding the array of factors to consider across ADC transfer and supply chain that could impact product stability
• Developing ADC stability budgets to support product progression through clinical and commercial-stage process
• Contextualizing strategy with case study data demonstrating strong ADC product stability